In an interview with BioPharma BoardRoom, Eric Blair, GDMC’s Chief Business Officer, discusses the company's strategic use of Series A funding to pio...
Cencora’s FormularyDecisions has introduced a groundbreaking resource tailored for healthcare payers navigating the evolving landscape of cell and ge...
In a groundbreaking initiative poised to revolutionize cancer treatment, AstraZeneca announces a strategic $300 million investment in a cutting-edge facili...
The Express Genes offering, initially launched in November 2023, now extends to larger midiprep (10μg to 100 μg) and maxiprep (100μg to 1mg) DNA p...
The company's commitment to advancing human potential through science is evident in its transformative approach and a diverse portfolio of specialize...
“Myositis, believed to be driven by B cells, is a severe and potentially fatal autoimmune disease for which no curative therapy exists. Current treat...
NMDP BioTherapies℠, formerly Be The Match BioTherapies, announced that Tom Hochuli will serve as president, leading the organization into its promising f...
Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulti...
Tyruko® approved for all indications of reference medicine Tyruko® biosimilar to treat adults with highly active relapsing remitting multi...
The round also included premier investors such as WI Harper Group, a leading cross-border venture capital firm, and SEEDS Capital, the investment arm of go...
Safety and initial efficacy data from Stage 1 expected in the first half of 2024 Dose selection and initiation of Stage 2 to follow in the second half of ...
Biocytogen’s fully human antibody sequences were generated by proprietary RenMice strains, each engineered to lack a certain drug target gene. From M...
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, de...
As part of the agreement, Armatus will leverage Andelyn’s extensive experience in adeno-associated virus (AAV) production and its proprietary suspens...
© 2024 Biopharma Boardroom. All Rights Reserved.
